SRD5A2 and prostate adenocarcinoma: Within the group of Gleason score 7 patients in the TCGA-PRAD dataset (n = 158), 12 transcripts remained prognostic (Table 2, Fig. 2), with 1 negatively associated with BCR (SRD5A2) and 11 positively associated with BCR (BUB1, TPX2, NCAPG, UBE2C, MELK, CCNA2, CCNB1,CDK1, E2F2, DLGAP5, TMEM206,).